View in EDS

Ketamine treatment for depression: A model of care.

Saved in:
Bibliographic Details
Title: Ketamine treatment for depression: A model of care.
Authors: Bayes, Adam, Dong, Vanessa, Martin, Donel, Alonzo, Angelo, Kabourakis, Michael, Loo, Colleen
Source: Australian & New Zealand Journal of Psychiatry. Dec2021, Vol. 55 Issue 12, p1134-1143. 10p.
Subjects: Health policy, Clinical governance, Medical care, Patients, Individualized medicine, Conceptual structures, Mental depression, Ketamine, Patient safety, Dose-response relationship in biochemistry
Abstract: Objective: Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression. Ketamine differs from standard antidepressants in its speed of action, specific acute and cumulative side effects, risk of dependence and regulatory requirements. However, there is currently little guidance offering translation from research studies into clinical practice. We therefore detail a comprehensive model of care for ketamine treatment of depression. Method: We formulated a set of policies and procedures for a 'compassionate use' ketamine programme that developed out of our clinical research in ketamine. These policies and procedures were formulated into a detailed model of care. Results: The current Australian and New Zealand regulatory frameworks and professional bodies' recommendations regarding ketamine are detailed along with clinical governance and infrastructure considerations. We next describe a four-step model comprising initial assessment, pre-treatment, treatment and post-treatment phases. The model comprises thorough psychiatric and medical assessments examining patient suitability, a rigorous consenting process and structured safety monitoring across an acute treatment course or maintenance therapy. Our ketamine dose-titration method is detailed allowing flexible dosing of patients across a treatment course enabling individualised treatment. Conclusion: The model of care aims to bridge the gap between efficacy studies and clinical care outside of research settings as ketamine and related compounds become increasingly important therapies for treatment-resistant depression. [ABSTRACT FROM AUTHOR]
Copyright of Australian & New Zealand Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 154066543
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Ketamine treatment for depression: A model of care.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bayes%2C+Adam%22">Bayes, Adam</searchLink><br /><searchLink fieldCode="AR" term="%22Dong%2C+Vanessa%22">Dong, Vanessa</searchLink><br /><searchLink fieldCode="AR" term="%22Martin%2C+Donel%22">Martin, Donel</searchLink><br /><searchLink fieldCode="AR" term="%22Alonzo%2C+Angelo%22">Alonzo, Angelo</searchLink><br /><searchLink fieldCode="AR" term="%22Kabourakis%2C+Michael%22">Kabourakis, Michael</searchLink><br /><searchLink fieldCode="AR" term="%22Loo%2C+Colleen%22">Loo, Colleen</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Australian+%26+New+Zealand+Journal+of+Psychiatry%22">Australian & New Zealand Journal of Psychiatry</searchLink>. Dec2021, Vol. 55 Issue 12, p1134-1143. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Health+policy%22">Health policy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+governance%22">Clinical governance</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care%22">Medical care</searchLink><br /><searchLink fieldCode="DE" term="%22Patients%22">Patients</searchLink><br /><searchLink fieldCode="DE" term="%22Individualized+medicine%22">Individualized medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Conceptual+structures%22">Conceptual structures</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+depression%22">Mental depression</searchLink><br /><searchLink fieldCode="DE" term="%22Ketamine%22">Ketamine</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+safety%22">Patient safety</searchLink><br /><searchLink fieldCode="DE" term="%22Dose-response+relationship+in+biochemistry%22">Dose-response relationship in biochemistry</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: Ketamine and related compounds are emerging as rapidly acting therapies for treatment-resistant depression. Ketamine differs from standard antidepressants in its speed of action, specific acute and cumulative side effects, risk of dependence and regulatory requirements. However, there is currently little guidance offering translation from research studies into clinical practice. We therefore detail a comprehensive model of care for ketamine treatment of depression. Method: We formulated a set of policies and procedures for a 'compassionate use' ketamine programme that developed out of our clinical research in ketamine. These policies and procedures were formulated into a detailed model of care. Results: The current Australian and New Zealand regulatory frameworks and professional bodies' recommendations regarding ketamine are detailed along with clinical governance and infrastructure considerations. We next describe a four-step model comprising initial assessment, pre-treatment, treatment and post-treatment phases. The model comprises thorough psychiatric and medical assessments examining patient suitability, a rigorous consenting process and structured safety monitoring across an acute treatment course or maintenance therapy. Our ketamine dose-titration method is detailed allowing flexible dosing of patients across a treatment course enabling individualised treatment. Conclusion: The model of care aims to bridge the gap between efficacy studies and clinical care outside of research settings as ketamine and related compounds become increasingly important therapies for treatment-resistant depression. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Australian & New Zealand Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=154066543
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/00048674211039166
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1134
    Subjects:
      – SubjectFull: Health policy
        Type: general
      – SubjectFull: Clinical governance
        Type: general
      – SubjectFull: Medical care
        Type: general
      – SubjectFull: Patients
        Type: general
      – SubjectFull: Individualized medicine
        Type: general
      – SubjectFull: Conceptual structures
        Type: general
      – SubjectFull: Mental depression
        Type: general
      – SubjectFull: Ketamine
        Type: general
      – SubjectFull: Patient safety
        Type: general
      – SubjectFull: Dose-response relationship in biochemistry
        Type: general
    Titles:
      – TitleFull: Ketamine treatment for depression: A model of care.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bayes, Adam
      – PersonEntity:
          Name:
            NameFull: Dong, Vanessa
      – PersonEntity:
          Name:
            NameFull: Martin, Donel
      – PersonEntity:
          Name:
            NameFull: Alonzo, Angelo
      – PersonEntity:
          Name:
            NameFull: Kabourakis, Michael
      – PersonEntity:
          Name:
            NameFull: Loo, Colleen
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 00048674
          Numbering:
            – Type: volume
              Value: 55
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Australian & New Zealand Journal of Psychiatry
              Type: main
ResultId 1